10X Genomics Inc (TXG) Stock Price, Quote & News

Company Profile

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and singl...

Industry: Health Information Services

Sector: Healthcare

Phone: 925 401 7300

Website: www.10xgenomics.com

Address:

6230 Stoneridge Mall Road, Pleasanton, United States

MarketBeat May. 9 at 6:08 AM

10x Genomics Q1 Earnings Call Highlights $TXG https://www.marketbeat.com/instant-alerts/10x-genomics-q1-earnings-call-highlights-2026-05-09

0 · Reply

financials_please May. 8 at 8:42 PM

$TXG Some napkin math from the earnings call and past results when Xenium shipped. Current guidance is for 40 instruments to get placed in H2, heavily biased toward Q4 and maintaining max guidance of 625M (for now). Xenium sold 255 instruments in it's first year. With the demand/backlog they hint at, 200 instruments in 2027 is not unreasonable with ramp up. Assuming 80% utilization for the first 40 instruments that go to core facilities and other high volume customers, pull through for that batch in 2027 should be 64M. 2027 Atera instrument revenue should be 100M. If we assume the 200 instruments are sold in a linearly increasing rate then we can assume an average of 100 instruments consuming for the full year from that batch. Let's assume a lower rate of utilization for this batch to be safe, say 50%, which gives us 100M in revenue. Xenium placements should go down but Chromium revenue is expected to increase so let's call that a wash.

1 · Reply

BudskieMcgee May. 8 at 12:55 AM

$TXG what an earnings report! This thing is a serious sleeper. Once Atera launches and we start getting 4x pull through the revenue will be through the roof.

2 · Reply

StocktwitsEarnings May. 7 at 8:09 PM

$TXG Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.10 up 64.29% YoY • Reported revenue of $150.84M down -2.61% YoY • 10x Genomics is maintaining its full year 2026 revenue guidance of $600M to $625M, representing 0% to 4% growth over full year 2025, excluding non-recurring license and royalty revenue.

0 · Reply

Eddyg987 May. 4 at 10:14 PM

$TXG bad sign for analyzers after the $WGS earnings.

1 · Reply

Bates333 Apr. 30 at 4:04 PM

$TXG sold some more today.

0 · Reply

balaryan Apr. 30 at 11:37 AM

$TXG Going strong and long.. 🔥🔥

0 · Reply

LucasRMcCain Apr. 23 at 2:24 PM

$TXG Looks like the market really does not like that Atera announcement

3 · Reply

DonCorleone77 Apr. 21 at 5:05 PM

$TXG Attached is a Barclays analyst note regarding TXG issued today.

0 · Reply

IN0V8 Apr. 20 at 7:04 PM

$TXG Watch / Opportunity BofA Global Research raises price objective to $30.00 from $21.00

0 · Reply

10x Genomics price target raised to $22 from $20 at Morgan Stanley

2026-05-12T12:26:29.000Z - 1 day ago

10x Genomics price target raised to $20 from $17 at JPMorgan

2026-05-08T16:10:27.000Z - 4 days ago

10x Genomics price target raised to $23 from $17 at Deutsche Bank

2026-05-07T21:30:11.000Z - 5 days ago

10x Genomics reports Q1 EPS (10c), consensus (6c)

2026-05-07T21:28:54.000Z - 5 days ago

10x Genomics backs FY26 revenue view $600M-$625M, consensus $612.74M

May 7, 2026, 4:30 PM EDT - 5 days ago

10x Genomics Earnings Call Transcript: Q1 2026

May 7, 2026, 4:05 PM EDT - 5 days ago

10x Genomics Reports First Quarter 2026 Financial Results

Apr 29, 2026, 4:05 PM EDT - 13 days ago

10x Genomics to Participate in the BofA Securities 2026 Healthcare Conference

Apr 23, 2026, 7:00 AM EDT - 20 days ago

LiquidCell Dx Appoints Former Foundation Medicine, 10x Genomics and IDT Leader Mirna Jarosz as Chief Executive Officer; Names Former Foundation Medicine Chief Medical Officer Vincent A. Miller, MD, Senior Strategic Advisor

2026-04-20T14:03:59.000Z - 23 days ago

10x Genomics price target raised to $32 from $22 at Canaccord

2026-04-20T13:43:54.000Z - 23 days ago

10x Genomics price target raised to $30 from $21 at BofA

2026-04-19T17:10:44.000Z - 23 days ago

10x Genomics announces Atera, a new in situ spatial biology platform

Apr 18, 2026, 10:00 PM EDT - 24 days ago

10x Genomics Introduces Atera, a New Platform to Redefine How Biology is Measured and Understood

Apr 15, 2026, 4:05 PM EDT - 27 days ago

10x Genomics to Report First Quarter 2026 Financial Results on May 7, 2026

2026-04-14T10:50:31.000Z - 4 weeks ago

10x Genomics price target raised to $30 from $22 at Barclays

2026-04-07T10:15:11.000Z - 5 weeks ago

10x Genomics price target raised to $24 from $18 at Citi

2026-03-30T21:45:11.000Z - 6 weeks ago

10x Genomics upgraded to Outperform from Market Perform at William Blair

Mar 25, 2026, 7:00 AM EDT - 7 weeks ago

Bioptimus Announces STELA: The World's Largest Clinically Linked Spatial Biology Atlas, alongside key partners 10x Genomics and Broad Clinical Labs

2026-03-20T00:20:12.000Z - 7 weeks ago

Cathie Wood’s ARK Investment buys 92K shares of 10x Genomics today

Mar 17, 2026, 8:00 AM EDT - 2 months ago

PerturbAI Launches from Stealth, Unveils the World's Largest In Vivo CRISPR Atlas

2026-03-16T16:06:47.000Z - 2 months ago

10x Genomics falls -13.8%

Mar 3, 2026, 11:50 AM EST - 2 months ago

10x Genomics Transcript: TD Cowen 46th Annual Health Care Conference

2026-03-02T12:34:44.000Z - 2 months ago

10x Genomics price target raised to $25 from $20 at Stifel

Feb 19, 2026, 4:05 PM EST - 2 months ago

10x Genomics to Participate in the 46th Annual TD Cowen Health Care Conference

Feb 12, 2026, 4:30 PM EST - 3 months ago

10x Genomics Earnings Call Transcript: Q4 2025

Feb 12, 2026, 4:05 PM EST - 3 months ago

10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026

Feb 4, 2026, 9:00 AM EST - 3 months ago

PharosAI and 10x Genomics Partner to Transform Cancer Research with AI and Spatial Biology

Jan 22, 2026, 4:05 PM EST - 3 months ago

10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

Jan 12, 2026, 11:15 AM EST - 4 months ago

10x Genomics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 9:11 AM EST - 4 months ago

10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease

Jan 12, 2026, 9:10 AM EST - 4 months ago

10x Genomics to Advance Research in Diagnostic Applications of Tumor Single Cell and Spatial Profiling

Jan 12, 2026, 9:00 AM EST - 4 months ago

Cancer Research Institute Launches Transformative AI-Driven Immuno-Oncology Initiative Powered by 10x Genomics Technology

Jan 11, 2026, 12:00 PM EST - 4 months ago

10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results

Jan 7, 2026, 7:05 AM EST - 4 months ago

CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response

CDNA

Dec 29, 2025, 4:05 PM EST - 4 months ago

10x Genomics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 18, 2025, 11:20 AM EST - 6 months ago

10x Genomics Transcript: Wolfe Research Healthcare Conference 2025

Nov 18, 2025, 9:00 AM EST - 6 months ago

New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics' Xenium

Nov 11, 2025, 4:05 PM EST - 6 months ago

10x Genomics to Participate in the Wolfe Research Healthcare Conference 2025

Nov 6, 2025, 4:30 PM EST - 6 months ago

10x Genomics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:05 PM EST - 6 months ago

10x Genomics Reports Third Quarter 2025 Financial Results

Oct 29, 2025, 9:00 AM EDT - 7 months ago

10x Genomics Launches the Next Generation of Chromium Flex to Empower Scientists to Massively Scale Single Cell Research

Oct 20, 2025, 12:30 PM EDT - 7 months ago

10x Genomics and Anthropic Partner to Make Single Cell and Spatial Analysis More Accessible Through Claude for Life Sciences

Oct 9, 2025, 4:05 PM EDT - 7 months ago

10x Genomics to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 9, 2025, 8:00 AM EDT - 7 months ago

Parse Biosciences Invalidates Scale Biosciences (now 10x Genomics) Patent

Sep 10, 2025, 11:30 AM EDT - 8 months ago

10x Genomics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 9:00 AM EDT - 8 months ago

CLISEQ, 10X Genomics and Weizmann Institute to Investigate Single Cell Applications in Hematology Clinical Diagnostics

Aug 27, 2025, 4:05 PM EDT - 9 months ago

10x Genomics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 19, 2025, 9:00 AM EDT - 9 months ago

10x Genomics Launches Xenium Protein, Advancing Spatial Biology by Enabling Same-Cell RNA and Protein Analysis

Aug 7, 2025, 4:30 PM EDT - 9 months ago

10x Genomics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 9 months ago

10x Genomics Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:04 PM EDT - 9 months ago

10x Genomics to Acquire Scale Biosciences

Jul 17, 2025, 9:00 AM EDT - 10 months ago

10x Genomics and A*STAR Genome Institute of Singapore Launch TISHUMAP Study to Advance AI-Driven Drug Target Discovery

Jul 10, 2025, 4:05 PM EDT - 10 months ago

10x Genomics to Report Second Quarter 2025 Financial Results on August 7, 2025

May 14, 2025, 4:05 PM EDT - 1 year ago

10x Genomics Announces Patent Litigation Settlement Agreement with Bruker

May 13, 2025, 2:20 PM EDT - 1 year ago

10x Genomics Transcript: Bank of America 2025 Healthcare Conference

May 8, 2025, 4:30 PM EDT - 1 year ago

10x Genomics Earnings Call Transcript: Q1 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

10x Genomics Reports First Quarter 2025 Financial Results

Apr 30, 2025, 4:05 PM EDT - 1 year ago

10x Genomics to Participate in the BofA Securities 2025 Healthcare Conference

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Vizgen Announces End of Litigation with 10x Genomics and Harvard University

Mar 4, 2025, 11:10 AM EST - 1 year ago

10x Genomics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 4:05 PM EST - 1 year ago

10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products

Feb 23, 2025, 11:30 AM EST - 1 year ago

10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis

Feb 18, 2025, 4:05 PM EST - 1 year ago

10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference

Feb 12, 2025, 7:19 PM EST - 1 year ago

Trump's Cuts to Medical Research Are Hurting These Stocks

ILMN PACB

Feb 12, 2025, 4:30 PM EST - 1 year ago

10x Genomics Earnings Call Transcript: Q4 2024

Feb 12, 2025, 4:05 PM EST - 1 year ago

10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025

Feb 6, 2025, 8:30 AM EST - 1 year ago

Chan Zuckerberg Initiative Launches Billion Cells Project with 10x Genomics and Ultima Genomics to Advance AI in Biology

Feb 4, 2025, 8:59 AM EST - 1 year ago

Parse Biosciences Invalidates All 10x Genomics' Patent Claims Asserted Against Its Products

Jan 31, 2025, 6:34 AM EST - 1 year ago

Spatial Omics Research Report 2023-2034: Market to reach $1.09 Billion - 10x Genomics Enhances Spatial OMICS with New Visium Spatial Gene Expression for FFPE

Jan 28, 2025, 4:05 PM EST - 1 year ago

10x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025

Jan 13, 2025, 10:30 AM EST - 1 year ago

10x Genomics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 2, 2025, 4:05 PM EST - 1 year ago

10x Genomics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 23, 2024, 4:05 PM EST - 1 year ago

U.S. District Court Awards 10x Genomics Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation's GeoMx Products

BRKR

Nov 19, 2024, 1:00 PM EST - 1 year ago

10x Genomics Transcript: Wolfe Research Healthcare Conference 2024

Nov 7, 2024, 4:05 PM EST - 1 year ago

10x Genomics to Present at the Wolfe Research 2024 Healthcare Conference

Oct 31, 2024, 8:00 AM EDT - 1 year ago

TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative

Oct 29, 2024, 4:30 PM EDT - 1 year ago

10x Genomics Earnings Call Transcript: Q3 2024

Oct 29, 2024, 4:05 PM EDT - 1 year ago

10x Genomics Reports Third Quarter 2024 Financial Results

Oct 15, 2024, 4:05 PM EDT - 1 year ago

10x Genomics Delivers 'Single Cell for a Single Cent' with New Chromium Launches

MarketBeat May. 9 at 6:08 AM

10x Genomics Q1 Earnings Call Highlights $TXG https://www.marketbeat.com/instant-alerts/10x-genomics-q1-earnings-call-highlights-2026-05-09

0 · Reply

financials_please May. 8 at 8:42 PM

1 · Reply

BudskieMcgee May. 8 at 12:55 AM

$TXG what an earnings report! This thing is a serious sleeper. Once Atera launches and we start getting 4x pull through the revenue will be through the roof.

2 · Reply

StocktwitsEarnings May. 7 at 8:09 PM

0 · Reply

Eddyg987 May. 4 at 10:14 PM

$TXG bad sign for analyzers after the $WGS earnings.

1 · Reply

Bates333 Apr. 30 at 4:04 PM

$TXG sold some more today.

0 · Reply

balaryan Apr. 30 at 11:37 AM

$TXG Going strong and long.. 🔥🔥

0 · Reply

LucasRMcCain Apr. 23 at 2:24 PM

$TXG Looks like the market really does not like that Atera announcement

3 · Reply

DonCorleone77 Apr. 21 at 5:05 PM

$TXG Attached is a Barclays analyst note regarding TXG issued today.

0 · Reply

IN0V8 Apr. 20 at 7:04 PM

$TXG Watch / Opportunity BofA Global Research raises price objective to $30.00 from $21.00

0 · Reply

AlertsAndNews Apr. 19 at 10:11 PM

$TXG 10x Genomics Introduces Atera, a New Platform to Redefine How Biology is Measured and Understood " announced Atera, a new in situ spatial biology platform engineered to deliver whole-transcriptome spatial analysis with single-cell sensitivity at unprecedented scale."

0 · Reply

mkultra Apr. 19 at 3:42 AM

$TXG $400/share https://www.prnewswire.com/news-releases/10x-genomics-introduces-atera-a-new-platform-to-redefine-how-biology-is-measured-and-understood-302746542.html

0 · Reply

financials_please Apr. 19 at 2:23 AM

$TXG that unveil makes me think next week will be great, let's see though...

0 · Reply

BudskieMcgee Apr. 17 at 1:23 PM

$TXG everybody ready?!! Tomorrow is the big day where the Impossible becomes possible! LFG! 🚀🚀🚀

1 · Reply

JFDI Apr. 17 at 1:00 PM

$TXG go time

1 · Reply

Bates333 Apr. 16 at 8:09 PM

$TXG sold a fourth of my position today

1 · Reply

IN0V8 Apr. 15 at 3:47 PM

$TXG Barclays raises target price to $30 from $22

0 · Reply

james899 Apr. 15 at 3:14 PM

$TXG Here's my technical view, although I know very little about TA: from here I would expect it to drop back ~ towards the 200 SMA (currently 16,30). There we get a confirmation and it keeps going up. November 2022 and September 2024 could be the resistances that temporarily bring us back down. Does that make any sense 🤔

1 · Reply

dark_gamma Apr. 14 at 2:38 PM

$NFLX OPTIONS LEVELS Updated: 2026-04-14 Key Levels to Watch: - Call Wall: $105.00 - Put Wall: $102.00 - Gamma Flip Point: $102.00 Whale Activity: - Dark Gamma Level: $103.14 - Whale Positions: • Whale 1: $103.16 • Whale 2: $103.01 • Whale 3: $101.97 • Whale 4: $TXG • Whale 5: $101.86 Volatility Ranges: - Upper Bound (1σ): $105.64 - Upper Bound (2σ): $108.12 - Lower Bound (1σ): $100.68 - Lower Bound (2σ): $98.20 Disclaimer: Levels updated daily. Please consult with a financial advisor for personalized trading advice.

0 · Reply

BudskieMcgee Apr. 10 at 2:57 AM

$TXG shorts let this go. All about fundamentals now. Big reveal coming on 4.18. This thing is set up to 🌖!!!!

0 · Reply

Bates333 Apr. 7 at 6:01 PM

$TXG @Professor thoughts?

1 · Reply

OfficialStocktwitsUser Apr. 3 at 3:09 AM

$TXG RSI: 64.65, MACD: 0.3931 Vol: 1.51, MA20: 19.72, MA50: 20.04 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Market Cap	2.62B
Revenue (ttm)	642.82M
Net Income (ttm)	-43.54M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6.77%
Debt to Equity Ratio	0.00

Volume	2,745,000
Avg Vol	2,454,060
Day's Range	N/A - N/A
Shares Out	127.75M
Stochastic %K	33%
Beta	2.05
Analysts	Sell
Price Target	$24.00